$BRTX
BioRestorative Therapies, Inc. Stock $brtx

$brtx Overview Financials Valuation SEC Filings Company Website

2022 Q4 Form 10-Q Financial Statement

#000149315222031668 Filed on November 14, 2022

Income Statement

Concept	2022 Q4	2022 Q3	2021 Q3
Revenue	$3.700K	$29.00K	$8.000K
YoY Change	-26.0%	262.5%	-46.67%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$4.012M	$3.650M	$3.459M
YoY Change	4.24%	5.5%	824.37%
% of Gross Profit
Research & Development	$673.6K	$989.2K	$237.4K
YoY Change	307.02%	316.65%	-5.43%
% of Gross Profit
Depreciation & Amortization	$31.80K	$31.22K	$21.57K
YoY Change	47.91%	44.74%	-15.31%
% of Gross Profit
Operating Expenses	$4.686M	$4.639M	$3.697M
YoY Change	16.72%	25.48%	491.22%
Operating Profit		-$4.610M	-$3.689M
YoY Change		24.97%
Interest Expense	$116.1K	$28.84K	-$495.6K
YoY Change	-154.31%	-105.82%	1062.99%
% of Operating Profit
Other Income/Expense, Net	$218.2K	-$46.13K	-$495.5K
YoY Change		-90.69%
Pretax Income	-$4.348M	-$4.656M	-$4.184M
YoY Change	-78.69%	11.27%	400.35%
Income Tax
% Of Pretax Income
Net Earnings	-$4.348M	-$4.656M	-$4.184M
YoY Change	-78.69%	11.27%	400.35%
Net Earnings / Revenue	-117501.35%	-16054.57%	-52302.88%
Basic Earnings Per Share		-$1.28	-$4.99
Diluted Earnings Per Share	-$1.19	-$1.278M	-$4.989M
COMMON SHARES
Basic Shares Outstanding	3.674M shares	3.646M shares
Diluted Shares Outstanding		3.642M shares	838.7K shares

Balance Sheet

Concept	2022 Q4	2022 Q3	2021 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$14.75M	$16.49M	$1.130M
YoY Change	-29.85%	1359.37%	541.92%
Cash & Equivalents	$1.677M	$6.573M	$1.130M
Short-Term Investments	$13.07M	$9.914M
Other Short-Term Assets	$363.1K	$356.1K	$31.96K
YoY Change	-16.76%	1014.05%	36.35%
Inventory
Prepaid Expenses
Receivables	$16.00K	$45.00K	$8.000K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$15.13M	$16.89M	$1.170M
YoY Change	-29.53%	1343.81%	445.48%
LONG-TERM ASSETS
Property, Plant & Equipment	$261.0K	$231.3K	$397.0K
YoY Change	586.98%	-41.73%	-25.31%
Goodwill
YoY Change
Intangibles	$803.4K	$530.3K
YoY Change	36.24%
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$1.306M	$1.032M	$1.005M
YoY Change	32.54%	2.69%	-17.22%
TOTAL ASSETS
Total Short-Term Assets	$15.13M	$16.89M	$1.170M
Total Long-Term Assets	$1.306M	$1.032M	$1.005M
Total Assets	$16.43M	$17.92M	$2.175M
YoY Change	-26.81%	723.9%	52.21%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$170.9K	$468.5K	$124.6K
YoY Change	236.24%	276.12%	145.83%
Accrued Expenses	$130.1K	$114.6K	$704.7K
YoY Change	-3.63%	-83.73%	237.05%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change			-100.0%
Long-Term Debt Due	$0.00	$0.00	$44.17K
YoY Change	-100.0%	-100.0%
Total Short-Term Liabilities	$440.3K	$717.2K	$873.5K
YoY Change	21.02%	-17.89%	-36.45%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$5.848M
YoY Change	-100.0%	-100.0%
Other Long-Term Liabilities	$162.3K	$198.7K	$332.8K
YoY Change	-46.19%	-40.28%	-97.8%
Total Long-Term Liabilities	$162.3K	$198.7K	$6.181M
YoY Change	-67.05%	-96.78%	-59.19%
TOTAL LIABILITIES
Total Short-Term Liabilities	$440.3K	$717.2K	$873.5K
Total Long-Term Liabilities	$162.3K	$198.7K	$6.181M
Total Liabilities	$602.6K	$915.9K	$7.054M
YoY Change	-29.64%	-87.02%	-57.3%
SHAREHOLDERS EQUITY
Retained Earnings	-$152.6M	-$148.3M
YoY Change	13.79%
Common Stock	$369.00	$365.00
YoY Change	4.53%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$15.83M	$17.00M	-$4.879M
YoY Change
Total Liabilities & Shareholders Equity	$16.43M	$17.92M	$2.175M
YoY Change	-26.81%	723.9%	52.21%

Cashflow Statement

Concept	2022 Q4	2022 Q3	2021 Q3
OPERATING ACTIVITIES
Net Income	-$4.348M	-$4.656M	-$4.184M
YoY Change	-78.69%	11.27%	400.35%
Depreciation, Depletion And Amortization	$31.80K	$31.22K	$21.57K
YoY Change	47.91%	44.74%	-15.31%
Cash From Operating Activities	-$1.573M	-$1.452M	-$629.4K
YoY Change	37.41%	130.65%	20.32%
INVESTING ACTIVITIES
Capital Expenditures	$217.6K	$24.61K
YoY Change	-809.65%
Acquisitions
YoY Change
Other Investing Activities	-$3.106M	-$9.934M
YoY Change
Cash From Investing Activities	-$3.323M	-$9.909M
YoY Change	10738.85%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$0.00
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	0.000	0.000	0.000
YoY Change	-100.0%		-100.0%
NET CHANGE
Cash From Operating Activities	-1.573M	-1.452M	-629.4K
Cash From Investing Activities	-3.323M	-9.909M
Cash From Financing Activities	0.000	0.000	0.000
Net Change In Cash	-4.897M	-11.36M	-629.4K
YoY Change	-124.61%	1705.1%	415.4%
FREE CASH FLOW
Cash From Operating Activities	-$1.573M	-$1.452M	-$629.4K
Capital Expenditures	$217.6K	$24.61K
Free Cash Flow	-$1.791M	-$1.476M
YoY Change	60.71%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022Q3	BRTX	Gain On Ppp Loan Forgiveness GainOnPppLoanForgiveness		usd
CY2021Q3	BRTX	Gain On Ppp Loan Forgiveness GainOnPppLoanForgiveness		usd
	BRTX	Gain On Ppp Loan Forgiveness GainOnPppLoanForgiveness		usd
CY2022Q3	BRTX	Grant Income GrantIncome		usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities		usd
	dei	Entity Central Index Key EntityCentralIndexKey	0001505497
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
CY2021Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent		usd
CY2022Q3	us-gaap	Loans Payable Current LoansPayableCurrent		usd
CY2022Q3	us-gaap	Long Term Loans Payable LongTermLoansPayable		usd
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities		usd
	us-gaap	Payments To Acquire Productive Assets PaymentsToAcquireProductiveAssets		usd
CY2021Q3	BRTX	Grant Income GrantIncome		usd
	BRTX	Grant Income GrantIncome		usd
CY2021Q3	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense		usd
	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense		usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity		usd
CY2022Q3	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation		usd
CY2021Q1	BRTX	Shares Issued In Cashless Exercise Of Warrants SharesIssuedInCashlessExerciseOfWarrants		usd
CY2021Q3	BRTX	Shares Issued In Cashless Exercise Of Warrants SharesIssuedInCashlessExerciseOfWarrants		usd
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium		usd
	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss		usd
	us-gaap	Share Based Compensation ShareBasedCompensation		usd
	BRTX	Shares Issued In Settlement Of Litigation SharesIssuedInSettlementOfLitigation		usd
	BRTX	Gain On Ppp Loan Forgiveness GainOnPppLoanForgiveness		usd
	us-gaap	Proceeds From Repayments Of Debt ProceedsFromRepaymentsOfDebt		usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities		usd
	us-gaap	Stock Issued1 StockIssued1		usd
	BRTX	Bifurcated Embedded Conversion Options And Warrants Recorded As Derivative Liability And Debt Discount BifurcatedEmbeddedConversionOptionsAndWarrantsRecordedAsDerivativeLiabilityAndDebtDiscount		usd
	BRTX	Accrued Dip Expenses Exchanged For Convertible Notes AccruedDipExpensesExchangedForConvertibleNotes		usd
CY2021Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure		usd
CY2022Q3	BRTX	Accrued Research And Development Expenses AccruedResearchAndDevelopmentExpenses		usd
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2022-09-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-37603
	dei	Entity Registrant Name EntityRegistrantName	BIORESTORATIVE THERAPIES, INC.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	91-1835664
	dei	Entity Address Address Line1 EntityAddressAddressLine1	40 Marcus Drive
	dei	Entity Address City Or Town EntityAddressCityOrTown	Melville
	dei	Entity Address State Or Province EntityAddressStateOrProvince	NY
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	11747
	dei	City Area Code CityAreaCode	(631)
	dei	Local Phone Number LocalPhoneNumber	760-8100
	dei	Security12b Title Security12bTitle	Common Stock, $0.0001 par value
	dei	Trading Symbol TradingSymbol	BRTX
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
	dei	Entity Bankruptcy Proceedings Reporting Current EntityBankruptcyProceedingsReportingCurrent	true
CY2022Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	3673629	shares
CY2022Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	6573111	usd
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	436181	usd
CY2022Q3	us-gaap	Assets Current AssetsCurrent	16887824	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	21026727	usd
CY2022Q3	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	9913667	usd
CY2022Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	45000	usd
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	5000	usd
CY2022Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	356046	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	21467908	usd
CY2022Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	231324	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	37993	usd
CY2022Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	270772	usd
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	357805	usd
CY2022Q3	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	530298	usd
CY2022Q3	us-gaap	Liabilities Current LiabilitiesCurrent	717179	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	363822	usd
CY2021Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	589740	usd
CY2022Q3	us-gaap	Assets Assets	17920218	usd
CY2021Q4	us-gaap	Assets Assets	22453446	usd
CY2022Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	468501	usd
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	50827	usd
CY2022Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	114647	usd
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	134970	usd
CY2022Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	134031	usd
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	119055	usd
CY2021Q4	us-gaap	Loans Payable Current LoansPayableCurrent	58970	usd
CY2022Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	198724	usd
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	301645	usd
CY2021Q4	us-gaap	Long Term Loans Payable LongTermLoansPayable	191030	usd
CY2022Q3	us-gaap	Liabilities Liabilities	915903	usd
CY2021Q4	us-gaap	Liabilities Liabilities	856497	usd
CY2022Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2022Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2022Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	75000000	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	75000000	shares
CY2022Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	3646450	shares
CY2022Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	3646450	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	3520391	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	3520391	shares
CY2022Q3	us-gaap	Common Stock Value CommonStockValue	365	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	353	usd
CY2022Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	165281862	usd
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	155727292	usd
CY2022Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-148293344	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-134146128	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	17004315	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	21596949	usd
CY2022Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	17920218	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	22453446	usd
CY2022Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	29000	usd
CY2021Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	8000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	116100	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	41000	usd
CY2022Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	989170	usd
CY2021Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	237410	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2839731	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	563562	usd
CY2021Q3	us-gaap	Interest Expense InterestExpense	495545	usd
	us-gaap	Interest Expense InterestExpense	104465	usd
CY2022Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3649530	usd
CY2021Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3459277	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	11568490	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	21776044	usd
CY2022Q3	us-gaap	Operating Expenses OperatingExpenses	4638700	usd
CY2021Q3	us-gaap	Operating Expenses OperatingExpenses	3696687	usd
	us-gaap	Operating Expenses OperatingExpenses	14408221	usd
	us-gaap	Operating Expenses OperatingExpenses	22339606	usd
CY2022Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-4609700	usd
CY2021Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-3688687	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-14292121	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-22298606	usd
CY2022Q3	us-gaap	Interest Expense InterestExpense	28841	usd
	us-gaap	Interest Expense InterestExpense	1601551	usd
	BRTX	Gain On Ppp Loan Forgiveness GainOnPppLoanForgiveness	250000	usd
	BRTX	Grant Income GrantIncome	16654	usd
CY2022Q3	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	17284	usd
	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	17284	usd
CY2022Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-46125	usd
CY2021Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-495545	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	144905	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1601551	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-4655825	usd
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-4184232	usd
	us-gaap	Net Income Loss NetIncomeLoss	-14147216	usd
	us-gaap	Net Income Loss NetIncomeLoss	-23900157	usd
CY2022Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.28
CY2021Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-4.99
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-3.93
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-30.31
CY2022Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	3642215	shares
CY2021Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	838689	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	3602979	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	788564	shares
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	21596949	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	1164135	usd
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	2138949	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	72819	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-4816150	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	20156702	usd
CY2022Q2	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	1190350	usd
CY2022Q2	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	1865297	usd
CY2022Q2	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	48504	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-4675241	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	18585612	usd
CY2022Q3	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	1209231	usd
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	1068498	usd
	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	-19895	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	88751	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	67612	usd
	BRTX	Share Based Compensation Options ShareBasedCompensationOptions	5869543	usd
	BRTX	Share Based Compensation Options ShareBasedCompensationOptions	17422328	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	121323	usd
CY2022Q3	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	1865297	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-4655825	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	17004315	usd
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	-1331492	usd
CY2021Q1	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	213673	usd
CY2021Q1	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	179098	usd
CY2021Q1	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	13897669	usd
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-15653330	usd
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	-2694382	usd
CY2021Q2	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	103703	usd
CY2021Q2	BRTX	Shares Issued In Cashless Exercise Of Warrants SharesIssuedInCashlessExerciseOfWarrants	-82131	usd
CY2021Q2	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	1164135	usd
CY2021Q2	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	1762329	usd
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-4062595	usd
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	-3808941	usd
CY2021Q3	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	21000	usd
CY2021Q3	BRTX	Fair Market Value Of Beneficial Conversion Feature And Warrants Issued With Convertible Notes Payable Instruments FairMarketValueOfBeneficialConversionFeatureAndWarrantsIssuedWithConvertibleNotesPayableInstruments	166404	usd
CY2021Q3	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	1164135	usd
CY2021Q3	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	1762330	usd
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-4184232	usd
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	-4879304	usd
	us-gaap	Net Income Loss NetIncomeLoss	-14147216	usd
	us-gaap	Net Income Loss NetIncomeLoss	-23900157	usd
	BRTX	Share Based Compensation Restricted Stock Award ShareBasedCompensationRestrictedStockAward	3563716	usd
	BRTX	Share Based Compensation Restricted Stock Award ShareBasedCompensationRestrictedStockAward	2507368	usd
	BRTX	Shares Issued In Settlement Of Litigation SharesIssuedInSettlementOfLitigation	21000	usd
	BRTX	Gain On Ppp Loan Forgiveness GainOnPppLoanForgiveness	250000	usd
	BRTX	Noncash Lease Expense NoncashLeaseExpense	87033	usd
	BRTX	Noncash Lease Expense NoncashLeaseExpense	87033	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	40000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-9000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-80135	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-73451	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	417674	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	5707	usd
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-20321	usd
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	528015	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-87945	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-74749	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-4297412	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2184894	usd
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	9933562	usd
	us-gaap	Payments To Acquire Productive Assets PaymentsToAcquireProductiveAssets	222642	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-10156204	usd
	us-gaap	Proceeds From Repayments Of Debt ProceedsFromRepaymentsOfDebt	250000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	250000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-14453616	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-1934894	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	21026727	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	3064610	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	6573111	usd
CY2021Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	1129716	usd
	us-gaap	Stock Issued1 StockIssued1	317376	usd
	BRTX	Bifurcated Embedded Conversion Options And Warrants Recorded As Derivative Liability And Debt Discount BifurcatedEmbeddedConversionOptionsAndWarrantsRecordedAsDerivativeLiabilityAndDebtDiscount	166404	usd
	BRTX	Accrued Dip Expenses Exchanged For Convertible Notes AccruedDipExpensesExchangedForConvertibleNotes	698901	usd
CY2021Q4	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	1-for-4,000
CY2021Q4	us-gaap	Common Stock Shares Subscriptions CommonStockSharesSubscriptions	23000000	usd
CY2021Q4	BRTX	Securities Pursuant Aggregate Shares SecuritiesPursuantAggregateShares	2300000	shares
CY2021Q4	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	2645000	shares
	us-gaap	Net Income Loss NetIncomeLoss	-14100000	usd
CY2022Q3	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	9600000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-4300000	usd
	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<p id="xdx_846_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_zTzdETeYIOhe" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span id="xdx_867_zAZfcGMOuQT8">Prior Period Reclassifications</span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="background-color: white">Certain prior period amounts have been reclassified for consistency with current period presentation. These reclassifications had no effect on the condensed consolidated statements of operations or cash flows.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	5284121	shares
	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_848_eus-gaap--UseOfEstimates_z4gzFz6WXIeh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_866_zsh6WmBFjAY7">Use of Estimates</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of the unaudited condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, equity-based transactions, revenue and expenses and disclosure of contingent liabilities at the date of the unaudited condensed consolidated financial statements. The Company bases its estimates and assumptions on historical experience, known or expected trends and various other assumptions that it believes to be reasonable. As future events and their effects cannot be determined with precision, actual results could differ from these estimates which may cause the Company’s future results to be affected.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company believes the following critical accounting policies affect its more significant judgments and estimates used in the preparation of the accompanying unaudited condensed consolidated financial statements. Significant estimates include the carrying value of intangible assets, deferred tax asset and valuation allowance, and assumptions used in the Black-Scholes option pricing model, such as expected volatility, risk-free interest rate, and expected dividend rate.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2022Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	29000	usd
CY2021Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	8000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	116100	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	41000	usd
CY2022Q3	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	16500000	usd
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	5812418	shares
CY2022Q3	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	4898305	usd
CY2022Q3	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	9913667	usd
CY2022Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	5812418	shares
CY2021Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	5284121	shares
CY2021Q3	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	12876004	shares
CY2020Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	664268	usd
CY2021	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	74528	usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	589740	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	59442	usd
CY2022Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	530298	usd
CY2022Q3	us-gaap	Employee Related Liabilities Current And Noncurrent EmployeeRelatedLiabilitiesCurrentAndNoncurrent	26250	usd
CY2021Q4	us-gaap	Employee Related Liabilities Current And Noncurrent EmployeeRelatedLiabilitiesCurrentAndNoncurrent	28370	usd
CY2021Q4	BRTX	Accrued Research And Development Expenses AccruedResearchAndDevelopmentExpenses	29672	usd
CY2022Q3	BRTX	Accrued General And Administrative Expenses AccruedGeneralAndAdministrativeExpenses	88397	usd
CY2021Q4	BRTX	Accrued General And Administrative Expenses AccruedGeneralAndAdministrativeExpenses	76928	usd
CY2022Q3	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	114647	usd
CY2021Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	134970	usd
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	1175000	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	2500000	shares
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Shares Issued In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod	838549	shares
CY2022Q3	BRTX	Description Of Stock Optopn Held By Officer And Director DescriptionOfStockOptopnHeldByOfficerAndDirector	(i) Lance Alstodt, the Company’s President, Chief Executive Officer and Chairman of the Board: 335,538 shares, (ii) Francisco Silva, the Company’s Vice President of Research and Development and a director: 335,538 shares; (iii) Robert Kristal, the Company’s Chief Financial Officer: 10,490 shares; (iv) Robert Paccasassi, the Company’s Vice President of Quality Assurance and Regulatory Compliance: 8,277 shares; (v) Nickolay Kukekov, one of the Company’s directors: 25,236 shares; (vi) Patrick F. Williams, one of the Company’s directors: 10,490 shares; and (vii) David Rosa, one of the Company’s directors: 10,490 shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	30	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	3273.00
CY2022Q3	us-gaap	Employee Benefits And Share Based Compensation EmployeeBenefitsAndShareBasedCompensation	1900000	usd
CY2021Q3	us-gaap	Employee Benefits And Share Based Compensation EmployeeBenefitsAndShareBasedCompensation	1700000	usd
	us-gaap	Employee Benefits And Share Based Compensation EmployeeBenefitsAndShareBasedCompensation	6000000.0	usd
	us-gaap	Employee Benefits And Share Based Compensation EmployeeBenefitsAndShareBasedCompensation	17400000	usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	25000	shares
	BRTX	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	4.88
CY2022Q3	BRTX	Unamortized Compensation Expense UnamortizedCompensationExpense	90000.00	usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	586959	shares
	BRTX	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	47.25
CY2021Q3	BRTX	Unamortized Compensation Expense UnamortizedCompensationExpense	3200000	usd
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	864609	shares
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	18.73
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	839639	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	18.73
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	25000	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	4.92
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	532045	shares
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	17.50
CY2022Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3100000	usd
CY2021Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2900000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	9600000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	19900000	usd
CY2022Q3	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	10800000	usd
	us-gaap	Operating Lease Payments OperatingLeasePayments	118779	usd
	BRTX	Operating Lease Liability Reduction OperatingLeaseLiabilityReduction	87945	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	122349	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	118779	usd
	us-gaap	Lease Cost LeaseCost	122349	usd
	us-gaap	Lease Cost LeaseCost	118779	usd
	us-gaap	Operating Lease Payments OperatingLeasePayments	122349	usd
	BRTX	Operating Lease Liability Reduction OperatingLeaseLiabilityReduction	74749	usd
CY2022Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	270772	usd
CY2021Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	386816	usd
CY2022Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	134031	usd
CY2021Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	114387	usd
CY2022Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	198724	usd
CY2021Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	332755	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	40783	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	168028	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	173060	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	381871	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	49116	usd
CY2022Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	332755	usd

Files In Submission

Name	View Source	Status
0001493152-22-031668-index-headers.html	Edgar Link	pending
0001493152-22-031668-index.html	Edgar Link	pending
0001493152-22-031668.txt	Edgar Link	pending
0001493152-22-031668-xbrl.zip	Edgar Link	pending
brtx-20220930.xsd	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-q.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
brtx-20220930_cal.xml	Edgar Link	unprocessable
brtx-20220930_lab.xml	Edgar Link	unprocessable
brtx-20220930_def.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
brtx-20220930_pre.xml	Edgar Link	unprocessable
form10-q_htm.xml	Edgar Link	completed
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$BRTX
BioRestorative Therapies, Inc. Stock $brtx

2022 Q4 Form 10-Q Financial Statement

#000149315222031668 Filed on November 14, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BRTX BioRestorative Therapies, Inc. Stock $brtx

2022 Q4 Form 10-Q Financial Statement

#000149315222031668 Filed on November 14, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BRTX
BioRestorative Therapies, Inc. Stock $brtx